Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US6441168 | BAYER HLTHCARE | Stable crystalline salts of 5-methyltetrahydrofolic acid |
Apr, 2020
(4 years ago) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US5798338 | BAYER HLTHCARE | Solid dosage forms that contain clathrates of 17α-ethinyl estradiol |
Jul, 2015
(8 years ago) | |
US6958326 | BAYER HLTHCARE | Cyclodextrin-drospirenone inclusion complexes |
Dec, 2021
(2 years ago) | |
US7163931 | BAYER HLTHCARE | Compositions of estrogen-cyclodextrin complexes |
Mar, 2022
(2 years ago) | |
US8617597 | BAYER HLTHCARE | Pharmaceutical composition containing a tetrahydrofolic acid |
Feb, 2030
(5 years from now) | |
US11617751 | BAYER HLTHCARE | Pharmaceutical composition containing a tetrahydrofolic acid |
Jul, 2030
(6 years from now) |
Safyral is owned by Bayer Hlthcare.
Safyral contains Drospirenone; Ethinyl Estradiol; Levomefolate Calcium.
Safyral has a total of 6 drug patents out of which 4 drug patents have expired.
Expired drug patents of Safyral are:
Safyral was authorised for market use on 16 December, 2010.
Safyral is available in tablet;oral dosage forms.
Safyral can be used as raise folate levels in women who choose to use an oral contraceptive as their method of contraception for the purpose of reducing the risk of a neural tube defect in a pregnancy, prevention of pregnancy.
The generics of Safyral are possible to be released after 17 July, 2030.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Product(NP) | Dec 16, 2013 |
Drugs and Companies using DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM ingredient
Market Authorisation Date: 16 December, 2010
Treatment: Prevention of pregnancy; Raise folate levels in women who choose to use an oral contraceptive as their method of contraception for the purpose of reducing the risk of a neural tube defect in a pregnan...
Dosage: TABLET;ORAL